仿制雷迪帕韦-索磷布韦治疗慢性丙型肝炎:一项真实世界观察性研究
该开放标签观察性研究纳入63例肝硬化(第1组)和65例非肝硬化(第2组)患者,分别接受仿制雷迪帕韦-索磷布韦联合每日1000-1200mg利巴韦林治疗12周和8周;另64例非肝硬化患者(第3组)单用该仿制药治疗8周。三组持续病毒学应答率(SVR12)分别为96.8%、96.9%和96.9%,方案总体耐受良好。
要点
- 基因1b型HCV感染:仿制雷迪帕韦-索磷布韦联合或不联合利巴韦林8或12周安全有效。
- 肝硬化组12周联合利巴韦林SVR12为96.8%(61/63),非肝硬化组8周联合利巴韦林为96.9%(63/65)。
- 非肝硬化组单药8周SVR12为96.9%(62/64);最常见不良事件为乏力(17.8%)、腹泻(10.9%)和头痛(9.9%)。
核心结论
- 8或12周仿制雷迪帕韦-索磷布韦联合或不联合利巴韦林对基因1b型HCV感染患者安全有效。
研究设计与样本
- 开放标签观察性研究,共纳入63例肝硬化患者(第1组)、65例非肝硬化患者(第2组)和64例非肝硬化患者(第3组)。
- 第1组接受仿制雷迪帕韦-索磷布韦联合每日1000-1200mg利巴韦林治疗12周;第2组接受相同联合方案治疗8周;第3组单用仿制雷迪帕韦-索磷布韦治疗8周。
- 主要疗效终点为治疗结束后第12周HCV RNA检测不到(SVR12),并收集安全性和药代动力学数据。
主要发现
- 187例患者完成治疗;3例肝硬化患者在治疗第5周观察到最新检测不到的HCV RNA。
- 意向性分析显示第1、2、3组SVR12率分别为96.8%(61/63)、96.9%(63/65)和96.9%(62/64)。
- 第3组1例患者在治疗结束后第4周复发。
- 最常见不良事件为乏力(17.8%)、腹泻(10.9%)和头痛(9.9%);4例患者因腹泻和呕吐停止治疗。
- 第2组1例患者因无力负担药物于第29天停止治疗,但该患者仍获得SVR12。
临床怎么用
- 作者认为,8或12周仿制雷迪帕韦-索磷布韦联合或不联合利巴韦林对基因1b型HCV感染患者安全有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Few patients from developing countries can afford brand name direct-acting antiviral agents for treating hepatitis C virus (HCV) infection, and controversy regarding the bioequivalence of generics exists. This study aimed to observe the safety and efficacy of 8 or 12weeks of generic ledipasvir-sofosbuvir with or without ribavirin for Chinese genotype 1b HCV-infected patients. METHODS: In this open-labelled observational study, 63 cirrhotic (group 1) and 65 non-cirrhotic (group 2) patients were administered generic ledipasvir-sofosbuvir plus 1000-1200mg of ribavirin daily for 12 and 8weeks, respectively; and 64 non-cirrhotic patients (group 3) received ledipasvir-sofosbuvir for 8weeks. The primary efficacy endpoint was undetectable HCV RNA at week 12 (SVR12) after cessation of therapy. Safety and pharmacokinetic data were collected. RESULTS: One hundred and eighty-seven patients completed treatment, and the latest undetectable HCV RNA was observed in three patients with cirrhosis at week 5 during treatment. Intention-to-treat analysis revealed 96.8% (61/63), 96.9% (63/65), and 96.9% (62/64) of SVR12 rates in groups 1, 2, and 3, respectively. One patient in group 3 relapsed at post-treatment week 4. The regimens were generally well-tolerated. The most common adverse events were fatigue (17.8%), diarrhea (10.9%), and headache (9.9%). Four patients discontinued therapy due to diarrhea and vomiting. One patient from group 2 discontinued treatment on day 29 because of drug-unaffordability; fortunately, she achieved SVR12. CONCLUSION: This study demonstrated that 8 or 12weeks of generic ledipasvir-sofosbuvir with or without ribavirin are safe and effective for patients with genotype 1b HCV infection. LAY SUMMARY: The price of Harvoni® has led to restrictions and access limitations in many developing and even developed countries with limited healthcare budgets. Gilead approved generic ledipasvir-sofosbuvir costs far less than Harvoni® and presents a similar cure rate for patients with chronic hepatitis C.
引用
- Zeng QL, Xu GH, Zhang JY, et al. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study. J Hepatol. 2017. PMID: 28189754. doi:10.1016/j.jhep.2017.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。